Pal-AHK vs NAD+
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Pal-AHK is the palmitoylated form of the AHK-Cu copper tripeptide, created by attaching a palmitic acid chain to enhance skin penetration and lipid bilayer affinity. The palmitoyl modification significantly improves dermal bioavailability compared to unmodified AHK, making it particularly effective in anti-aging and hair growth formulations.
- NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells that declines dramatically with age. It is critical for energy metabolism, DNA repair, and sirtuin activation. IV and subcutaneous NAD+ supplementation is used in anti-aging protocols and addiction recovery programs.
- Half-Life
- Extended (lipid depot effect in stratum corneum)
- Varies by route; IV provides direct cellular delivery
- Admin Route
- Topical
- IV, SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.01–0.05% in formulation
- 500–1000 mg
- Frequency
- Once or twice daily
- Daily for 4–10 days (loading), then monthly maintenance
- Key Benefits
- Enhanced skin penetration vs. unmodified AHK-Cu
- Stimulates dermal collagen and elastin production
- Promotes hair follicle anagen phase
- Antioxidant and wound healing activity
- Firming and plumping effect on aging skin
- Improved bioavailability via lipid bilayer incorporation
- Restored cellular energy production (ATP)
- Sirtuin activation for longevity and metabolic regulation
- Enhanced DNA repair capacity
- Improved mitochondrial function and biogenesis
- Cognitive clarity and mental energy
- Reduced inflammation
- Addiction withdrawal support (opioids, alcohol, benzodiazepines)
- Improved sleep quality
- Enhanced athletic endurance
- Side Effects
- Generally well-tolerated
- Mild irritation at high concentrations in sensitive skin
- Possible comedogenicity at very high palmitate concentrations (formulation-dependent)
- Flushing and warmth during IV infusion
- Nausea during rapid IV administration
- Chest tightness (from rapid infusion — slow the rate)
- Injection site irritation (subcutaneous)
- +1 more
- Stacks With
- —
- —